
Pemphigus vulgaris and pemphigus foliaceus are potentially life‐threatening autoimmune disorders triggered by immunoglobulin G (IgG) autoantibodies against mucosal and epidermal desmogleins. There is an unmet need for fast‐acting drugs that enable patients to achieve early sustained remission with reduced corticosteroid reliance. To investigate efgartigimod, an engineered Fc fragment that inhibits the activity of the neonatal Fc receptor, thereby reducing serum IgG levels, for treating pemphigus...
Like
Save
Share